Unknown

Dataset Information

Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.


ABSTRACT:

Introduction

Glutaminase inhibitors target cancer cells by blocking the conversion of glutamine to glutamate, thereby potentially interfering with anaplerosis and synthesis of amino acids and glutathione. The drug CB-839 has shown promising effects in preclinical experiments and is currently undergoing clinical trials in several human malignancies, including triple-negative breast cancer (TNBC). However, response to glutaminase inhibitors is variable and there is a need for identification of predictive response biomarkers. The aim of this study was to determine how glutamine is utilized in two patient-derived xenograft (PDX) models of breast cancer representing luminal-like/ER+ (MAS98.06) and basal-like/triple-negative (MAS98.12) breast cancer and to explore the metabolic effects o

SUBMITTER: Grinde MT 

PROVIDER: S-EPMC6518522 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature